This week might signify the start of institutional players entering the crypto scene, with trillions of dollars flowing into the market. However, this is dependent on the approval of spot Bitcoin ETFs by the US Securities and Exchange Commission (SEC). BlackRock, the world’s largest asset manager, expects its spot Bitcoin ETF, the Ishares Bitcoin Trust, to be approved this Wednesday, January 10th and excitement and optimism have reached a fever pitch.
At the same time, Injective (INJ) and InQubeta (QUBE) are receiving significant interest from investors. These cryptocurrencies stand at the intersection of innovation and growth, which positions them as the best coins to invest in.
In this post, we will cover the potential approval of BlackRock’s ETF application by the SEC this Wednesday. In addition to this, we will explain why investors are shifting their attention to Injective and InQubeta, two promising narratives in the crypto scene.
InQubeta (QUBE): The New Investor Favorite
InQubeta (QUBE) stands out among the new ICOs in the crypto scene at the moment. It recently soared past the $8.1 million fundraising milestone, a feat not many have been able to achieve. Further, it aims to solve the most pressing issues in one of the fastest-growing markets in the world, AI. Hence, the huge interest in this emerging crypto and top ICO is understandable.
Positioned at the crossroads of AI and blockchain, it aims to solve the fundraising and accessibility challenges in the AI sector with blockchain. It will become the first crowdfunding platform for AI startups through crypto. Worthy of note is its NFT marketplace, where real-world AI investments will be tokenized, and investors will be able to become early backers of promising AI startups. The coolest part? There will be no limit on investment.
In the sixth stage of its presale, at a token price of $0.01925, it represents a remarkably low entry point. With FOMO rising as the launch nears, now is a great time to position yourself. Meanwhile, according to experts, it will rally by 4,500% in the first six months after its launch, positioning it as the best new crypto to invest in.
Bitcoin (BTC) ETF: BlackRock Expects Approval this Week
Among the 11 spot Bitcoin ETF applicants, BlackRock stands out. It is the world’s largest asset manager, boasting $9.4 trillion in assets under management (AUM) as of 2023. According to popular crypto news, the asset manager expects the green light on its Bitcoin spot ETF application this Wednesday, January 10th.
Further, according to reports, BlackRock has lined up over $2 billion in capital for its spot Bitcoin ETF launch. With excitement almost in a frenzy, Bitcoin has assumed the spotlight again. With BTC set to skyrocket if this product is approved, it is positioned as the best crypto investment.
The fear of missing out (FOMO) is expected to soar before and after its approval. With a window of opportunity available, you can enter the Bitcoin market now and HODL in anticipation of its explosive growth.
Injective (INJ): Growing Investor Interest
Injective (INJ) is one of the most remarkable altcoins at the moment. It is a promising narrative thanks to the critical role it plays as a finance blockchain. It aims to power next-generation DeFi applications, including dApps (decentralized applications). As a result, it is expected to stay in demand, which positions Injective as one of the best cryptos to invest in.
Given the above, along with its staggering upside potential, it comes as no surprise that investors are doubling down on INJ. If you also wish to position yourself for significant gains, we suggest grabbing a bag of Injective and HODLing.
Conclusion
BlackRock expects to receive the green light on its spot Bitcoin ETF this week. Meanwhile, investors shift their focus to Injective and InQubeta, aiming to ride the market’s bullish wave to its fullest. If you wish to participate in the InQubeta presale, click the link below.
[thrive_leads id="228374"]
